Exhibit 5.1

| | |
25 March 2024 | | Our Ref: JT/MK/A6231- S16328 |
ASLAN Pharmaceuticals Limited
Walkers Corporate Limited
190 Elgin Avenue
George Town Grand
Cayman KY1-9008
Cayman Islands
Dear Sirs
ASLAN Pharmaceuticals Limited
We have acted as Cayman Islands legal advisers to ASLAN Pharmaceuticals Limited (the “Company”) in connection with the resale or other disposition of 125,000,000 of the Company’s ordinary shares of US$0.01 par value each (the “Warrant Shares”) initially issued to the Depositary (as defined in Schedule 1), which may be represented by 5,000,000 American Depositary Shares (the “Warrant ADSs”) issuable upon the exercise of the Warrants (as defined in the Securities Purchase Agreement, such agreement defined in Schedule 1) by certain selling shareholders identified in the Prospectus, pursuant to the Company’s registration statement on Form F-3 , including all amendments or supplements thereto (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), including the base prospectus contained therein (the “Prospectus”). We are furnishing this opinion as exhibit 5.1 to the Registration Statement.
For the purposes of giving this opinion, we have examined and relied upon the originals, copies or translations of the documents listed in Schedule 1.
In giving this opinion we have relied upon the assumptions set out in Schedule 2, which we have not independently verified.
We are Cayman Islands Attorneys at Law and express no opinion as to any laws other than the laws of the Cayman Islands in force and as interpreted at the date of this opinion. We have not, for the purposes of this opinion, made any investigation of the laws, rules or regulations of any other jurisdiction. Except as explicitly stated herein, we express no opinion in relation to any representation or warranty contained in any of the documents cited in this opinion nor upon matters of fact or the commercial terms of the transactions the subject of this opinion.
We have also assumed that prior to the issuance of any Warrant ADSs upon the exercise of the Warrants, and payment of the Warrant exercise price, number of Warrant ADSs, and certain other terms of issuance with respect to any specific letter of transmittal delivered under the Securities Purchase Agreement (a “Letter of Transmittal”) will be authorized and approved by the Company’s board of directors or a duly authorized committee thereof in accordance with the laws of the Cayman Islands (the “Corporate Proceedings”).
Walkers (Singapore) Limited Liability Partnership
UEN/Reg. No. T09LL0833E
3 Church Street, 16-02 Samsung Hub, Singapore 049483
T +65 6595 4670 F +65 6595 4671 www.walkersglobal.com
Bermuda I British Virgin Islands I Cayman Islands I Dubai I Dublin I Guernsey I Hong Kong I Jersey I London I Singapore